Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13410-021-00924-w http://scihub22266oqcxt.onion/10.1007/s13410-021-00924-w 33679040!7922709!33679040     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Diabetes+Dev+Ctries 2021 ; 41 (3): 377-382 Nephropedia Template TP {{tp|p=33679040|t=2021. Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus?|pdf=|usr=}}{{33679040}} gab.com Text Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus JO: Int J Diabetes Dev Ctries http://www.kidney.de/pget.php?&tw=1&pmid=33679040 #FOAvip INTRODUCTION: Diabetes has been linked with poorer outcomes in coronavirus disease (COVID-19) patients. However, the question to whether continue or withdraw metformin therapy in COVID-19 patients with type 2 diabetes mellitus remains contentious. This study aims to investigate the association between metformin and poor COVID-19 outcomes. METHODS: Eligible studies published up to 21 October 2020 were included and appraised for validity, importance, and applicability. The included studies were further ranked according to the level of evidence (LOE). RESULTS: Nine studies were included for further assessments, of which seven studies stated that metformin was not associated with poor COVID-19 outcomes (LOE II-V), while the other two with poorer designs stated otherwise (LOE V). Although metformin may increase the risk of developing acidosis and lactic acidosis (LOE IV), the observed risks were more accentuated in patients with severe COVID-19 disease or kidney impairment and in patients with > 2 daily metformin doses. Interestingly, one study revealed that metformin may even yield therapeutic role in reducing the risk of COVID-19 mortality (LOE II), although further studies are required to confirm these findings. CONCLUSIONS: Our findings indicated that metformin may be safely continued in COVID-19 patients. The benefit of metformin therapy with simultaneous continuous monitoring of COVID-19 severity and kidney function may outweigh the risks of lactic acidosis, of which incidence is relatively rare. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13410-021-00924-w. Twit Text FOAVip Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus ????Int J Diabetes Dev Ctries http://www.kidney.de/pget.php?&tw=1&pmid=33679040 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33679040 #FOAvip English Wikipedia <ref>{{Cite pmid|33679040}}</ref> Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus? #MMPMID33679040 Lazarus G; Suhardi IP; Wiyarta E; Rasyidah RA; Barliana JD Int J Diabetes Dev Ctries 2021[Jul]; 41 (3): 377-382 PMID33679040show ga INTRODUCTION: Diabetes has been linked with poorer outcomes in coronavirus disease (COVID-19) patients. However, the question to whether continue or withdraw metformin therapy in COVID-19 patients with type 2 diabetes mellitus remains contentious. This study aims to investigate the association between metformin and poor COVID-19 outcomes. METHODS: Eligible studies published up to 21 October 2020 were included and appraised for validity, importance, and applicability. The included studies were further ranked according to the level of evidence (LOE). RESULTS: Nine studies were included for further assessments, of which seven studies stated that metformin was not associated with poor COVID-19 outcomes (LOE II-V), while the other two with poorer designs stated otherwise (LOE V). Although metformin may increase the risk of developing acidosis and lactic acidosis (LOE IV), the observed risks were more accentuated in patients with severe COVID-19 disease or kidney impairment and in patients with > 2 daily metformin doses. Interestingly, one study revealed that metformin may even yield therapeutic role in reducing the risk of COVID-19 mortality (LOE II), although further studies are required to confirm these findings. CONCLUSIONS: Our findings indicated that metformin may be safely continued in COVID-19 patients. The benefit of metformin therapy with simultaneous continuous monitoring of COVID-19 severity and kidney function may outweigh the risks of lactic acidosis, of which incidence is relatively rare. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13410-021-00924-w. äIs there a need to reconsider the use of metformin in COVID-19 patient(epmc).pdf DeepDyve Pubget Overpricing